Drug Trial Radar · NCT05489887
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
93
Planned (sponsor's estimate)
Start
Sep 14, 2022
Primary completion
Sep 2029
Study completion Sep 2036
Sponsor
- Lead sponsor
- Giselle ShollerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Y-mAbs Therapeutics
- First posted
- Aug 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.
Conditions
- Neuroblastoma
Interventions
NaxitamabDrug
Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Complete Response (CR) rate per 1993 INRC guidelinesTime frame: 6 to 12 months
Locations
26 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama/Children's of Alabama
Birmingham, Alabama · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
UCSF Benioff Children's Hospital Oakland
Oakland, California · Recruiting
Rady Children's Hospital
San Diego, California · Recruiting
Connecticut Children's Hospital
Hartford, Connecticut · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
Arnold Palmer Hospital for Children
Orlando, Florida · Recruiting
Augusta University Health
Augusta, Georgia · Recruiting
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii · Recruiting
Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine
Louisville, Kentucky · Recruiting
Children's Hospital and Clinics of Minnesota
Minneapolis, Minnesota · Recruiting
Cardinal Glennon Children's Hospital
St Louis, Missouri · Recruiting
Levine Children's Hospital
Charlotte, North Carolina · Recruiting
Duke University
Durham, North Carolina · Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Withdrawn
Randall Children's Hospital
Portland, Oregon · Recruiting
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Dell Children's Blood and Cancer Center
Austin, Texas · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
GRAACC Hospital
São Paulo, São Paulo, Brazil · Recruiting
UHC Sainte-Justine
Montreal, Quebec, Canada · Recruiting
CHUQ
Québec, Quebec, Canada · Recruiting
CIUSSS de l'Estrie-CHUS
Sherbrooke, Quebec, Canada · Recruiting
Hospital Sant Joan de Déu
Esplugues de Llobregat, Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.